e-learning
resources
London 2016
Tuesday, 06.09.2016
Orphan diseases II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment response in hypersensitivity pneumonitis
Maria Laura Alberti (Ciudadela, Argentina), Maria Laura Alberti, Francisco Paulin, Martin Eduardo Fernández, Fabián Matías Caro
Source:
International Congress 2016 – Orphan diseases II
Session:
Orphan diseases II
Session type:
Thematic Poster
Number:
3919
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Maria Laura Alberti (Ciudadela, Argentina), Maria Laura Alberti, Francisco Paulin, Martin Eduardo Fernández, Fabián Matías Caro. Treatment response in hypersensitivity pneumonitis. Eur Respir J 2016; 48: Suppl. 60, 3919
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Related content which might interest you:
Effect of pirfenidone on IPF progression
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Rituximab for the treatment of chronic hypersensitivity pneumonitis
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
To treat or not to treat with corticosteroids radiation induced pneumonitis
Source: Annual Congress 2013 –New treatments and old dilemmas in the clinical management of lung diseases
Year: 2013
Influence of fungal colonization on 6-minute-walk test disance in patients with hypersensitivity pneumonitis
Source: Annual Congress 2013 –Modern approach to various clinical settings
Year: 2013
Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia
Source: International Congress 2014 – ILDs 3
Year: 2014
Novel lung function tests in patients with interstitial lung disease (ILD)
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Description of a murine model of acute pneumonitis hypersensitivity to pigeon serum
Source: International Congress 2014 – ILDs 2
Year: 2014
Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification?
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
The role of CCR2
+
CD4
+
T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Pulmonary function tests as predictors of mortality in patients with sarcoidosis
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
Changes in PH of exhaled breath condensate after specific inhalation challenge test, in patients with hypersensitivity pneumonitis
Source: International Congress 2014 – ILDs 3
Year: 2014
Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Asbestos-related disorders (ARDs): Influence of pleural plaques and pulmonary fibrosis due to asbestos exposure on lung function decline (LFD)
Source: International Congress 2014 – ILDs 5
Year: 2014
Mortality and survival predictor in chronic hypersensitivity pneumonitis
Source: International Congress 2016 – Sarcoidosis
Year: 2016
Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Hypoxic challenge testing in idiopathic pulmonary fibrosis
Source: International Congress 2016 – Orphan diseases I
Year: 2016
"Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease"
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept